Bayer acquires Vividion for $1.5B
Bayer has acquired Vividion Therapeutics for an upfront consideration of $1.5 billion and potential success-based milestone payments of up to $500 million. Read More
Bolt Threads leverages Ginkgo Bioworks' protein manufacturing platform
Biotechnology company Bolt Threads has formed a partnership with Ginkgo Bioworks to leverage the company's engineering technology for the development of synthetic products for the beauty and personal care industries. Read More
908 Devices reports revenue dip for Q2 2021
908 Devices reported a 26% decrease in revenues for the second quarter of 2021 compared to the same period in the prior year. Read More
Insilico uses artificial intelligence to develop kidney fibrosis drug candidate
Insilico Medicine has developed a preclinical candidate for kidney fibrosis that has the desired pharmacological properties and pharmacokinetic profile, and it has demonstrated highly promising results in in vitro and in vivo preclinical studies. Read More
Clarivate acquires Bioinfogate
Clarivate has acquired Bioinfogate, a life science research intelligence software developer. Read More
BioNTech takes over U.S. Kite cell therapy manufacturing site
BioNTech has completed the acquisition of a solid tumor neoantigen T-cell receptor R&D platform and clinical manufacturing facility from Kite, a Gilead company, in Gaithersburg, MD. Read More
Charles River reports 34% revenue spike in Q2
Charles River Laboratories reported a 34% increase in revenue for the second quarter of 2021 compared to the same period during the previous year. Read More
Waters reports Q2 earnings, cites commercial momentum
Lab equipment supplier Waters reported that its second-quarter sales rose by 31% to $682 million, up from $520 million in 2020. Read More
Tachyon, AbCellera to develop novel cancer antibody therapeutic
Tachyon Therapeutics and antibody discovery company AbCellera are teaming up to develop a first-in-class therapeutic antibody targeting the secreted extracellular protein left-right determination factor 1 (LEFTY1), which is expressed in advanced cancers. Read More
Sanofi to acquire mRNA partner Translate Bio for $3.2B
Sanofi is set to acquire COVID-19 development partner Translate Bio for $3.2 billion, a deal that will bring an mRNA platform, as well as an early stage pipeline in rare pulmonary diseases, into Sanofi's portfolio. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
